Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses early-onset telogen effluvium following COVID-19 infection and reports no new results, encouraging further exploration into its pathogenesis and differences compared to other acute forms.

This study found that telogen effluvium and trichodynia are common in patients after COVID-19, and their severity may be influenced by the severity of the COVID-19 infection.

This study reviewed how Anifrolumab, though often used in real-world settings for SLE patients with neurological symptoms, showed varying effectiveness and required cautious monitoring for adverse effects like thrombocytopenia and cerebrovascular events.

This review discusses recent advances in understanding the cellular, molecular, and genetic factors contributing to lupus erythematosus and reports no new experimental findings.

In this case report, treatment with anifrolumab led to significant improvement in symptoms for a 52-year-old woman with refractory systemic lupus erythematosus, including resolution of chronic lupus headaches resistant to previous therapies.